TRENDING :  Market Movers  |  Top 50   AMD (0%)    NFLX (0%)    SPY (0%)    SPX (0%)    DGAZ (0%)    TSLA (0%)    UGAZ (0%)    VXXB (0%)    VXX (0%)    TWLO (0%)    TLT (0%)    SQQQ (0%)    BOIL (0%)    BABA (0%)    SM (0%)    PCG (0%)    NBEV (0%)    MNGA (0%)    MBOT (0%)    INPX (0%)

 CRSP - CRISPR Therapeutics AG

$35.88 (0%)

Next Earnings



Analyst Rating

Quarterly Rating Chart


1=Strong Buy, 2=Buy, 3=Hold, 4=Underperform, 5=Sell
Price Targets
High $62.00
Low $62.00
Average $62.00
Current $35.88

CompanyAnalyst NamePT ActionActionRatingTargetDate
NeedhamAnnouncesInitiates Coverage OnBuy$62.0011/30/18
*Last 90 days


No recommendations found.

This list is limited to recommendations made in last 7 days only. Subscribe to a service to see all their recommendations.



Where Will CRISPR Therapeutics Be in 10 Years?

Predicting the future is never easy at least not with any hope of being remotely accurate But attempting to look 10 years in the future for an early stage biotech is especially tough CRISPR Therapeutics NASDAQ CRSP is about as early as you can get with early stage

The Best CRISPR Stock Gained 21% in 2018, While The Worst Lost 29%

What happened Last year was a roller coaster for the three leading CRISPR stocks CRISPR Therapeutics NASDAQ CRSP touched year to date gains of over 200 at one point Intellia Therapeutics NASDAQ NTLA eclipsed an 80 return at its best while Editas Medicine

Vertex, CRISPR's Sickle Disease Drug Gets FDA's Fast Track Tag

Vertex Pharmaceuticals Incorporated VRTX and partner CRISPR Therapeutics AG CRSP announced that the FDA has assigned Fast Track designation to their gene editing candidate CTX001 for the treatment of sickle cell disease SCD a severe hereditary form of anaemia The fast track status

Here's Why CRISPR Therapeutics Tanked 25.5% in December

What happened Shares of CRISPR Therapeutics NASDAQ CRSP 160 a clinical stage pioneer of the 160 genome editing technology everyone s talking about fell 25 5 in December according to data from S amp P Global Market Intelligence A market meltdown that dragged

Better Buy: CRISPR Therapeutics vs. Vertex Pharmaceuticals

The U S Food and Drug Administration recently granted fast track status to the first experimental new therapy from CRISPR Therapeutics NASDAQ CRSP That s a big deal for the young biotech and its collaboration partner Vertex Pharmaceuticals NASDAQ VRTX Both of

What Happened in the Stock Market Today

Yesterday s pessimism about the economy suddenly reversed Friday in the wake of a strong jobs report and comments by Federal Reserve Chairman Jay Powell that the Fed will be flexible on interest rates The Dow Jones Industrial Average DJINDICES DJI 160 and the S amp P

First Week of February 15th Options Trading For CRISPR Therapeutics (CRSP)

Investors in CRISPR Therapeutics AG Symbol CRSP saw new options begin trading this week for the February 15th expiration At Stock Options Channel our YieldBoost formula has looked up and down the CRSP options chain for the new February 15th contracts and identified one put and one

3 Gene Therapy Stocks to Play Biotech’s Future

InvestorPlace Stock Market News Stock Advice amp Trading Tips The recent weakness in the NASDAQ that has sent the tech heavy index into a bear market has created a buying opportunity Some of the hardest hit sectors are the ones with the brightest futures the problem is they

Don't Miss Chinese Biotechs

Chinese biotech has seen a 12 fold increase in venture capital funding in the last five years and that s not even touching on all the ways the Chinese government has started to back the space It s a huge opportunity for companies and patients and investors around the world are

Friday Sector Laggards: Drugs, Biotechnology Stocks

In trading on Friday drugs shares were relative laggards down on the day by about 2 6 Helping drag down the group were shares of Perrigo Company off about 25 and shares of Marinus Pharmaceuticals down about 11 1 on the day Also lagging the market Friday are biotechnology shares

Did China’s “Designer Babies” Just Open Pandora’s Box?

This past month a Chinese researcher revealed that he used CRISPR NASDAQ CRSP gene editing on human embryos and that the mother has now successfully given birth to twins These twin girls will go down in history as the world s first genetically engineered babies He conducted